Citations (44)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Justin D Lutz & Nina Isoherranen. (2012) In vitro-to-in vivo predictions of drug–drug interactions involving multiple reversible inhibitors. Expert Opinion on Drug Metabolism & Toxicology 8:4, pages 449-466.
Read now
Read now
Yiwen Gao, Duan Liu, Huijuan Wang, Juanli Zhu & Chao Chen. (2010) Functional characterization of five CYP2C8 variants and prediction of CYP2C8 genotype-dependent effects on in vitro and in vivo drug–drug interactions. Xenobiotica 40:7, pages 467-475.
Read now
Read now
Shu-Feng Zhou, Jun-Ping Liu & Balram Chowbay. (2009) Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metabolism Reviews 41:2, pages 89-295.
Read now
Read now
Thomas Forst & Andreas Pfützner. (2007) Fixed-dose combination of pioglitazone and glimepiride in the treatment of Type 2 diabetes mellitus. Expert Review of Endocrinology & Metabolism 2:3, pages 303-312.
Read now
Read now
James J Cali, Dongping Ma, Mary Sobol, Daniel J Simpson, Susan Frackman, Troy D Good, William J Daily & David Liu. (2006) Luminogenic cytochrome P450 assays. Expert Opinion on Drug Metabolism & Toxicology 2:4, pages 629-645.
Read now
Read now
S. Matsumoto, T. Hirama, H. J. Kim, K. Nagata & Y. Yamazoe. (2003) In vitro inhibition of human small intestinal and liver microsomal astemizole O -demethylation: different contribution of CYP2J2 in the small intestine and liver. Xenobiotica 33:6, pages 615-623.
Read now
Read now
Slobodan Rendic. (2002) Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metabolism Reviews 34:1-2, pages 83-448.
Read now
Read now
George Valsamakis & Sudhesh Kumar. (2000) Insulin action enhancers for the management of Type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy 1:7, pages 1413-1421.
Read now
Read now
Articles from other publishers (36)
Shankar S & Suneetha Vuppu. (2020) In vitro drug metabolism and pharmacokinetics of a novel thiazolidinedione derivative, a potential anticancer compound. Journal of Pharmaceutical and Biomedical Analysis 179, pages 113000.
Crossref
Crossref
Kenta Haraya, Motohiro Kato, Koji Chiba & Yuichi Sugiyama. (2017) Prediction of inter-individual variability on the pharmacokinetics of CYP2C8 substrates in human. Drug Metabolism and Pharmacokinetics 32:6, pages 277-285.
Crossref
Crossref
Janne T. Backman, Anne M. Filppula, Mikko Niemi & Pertti J. Neuvonen. (2015) Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions. Pharmacological Reviews 68:1, pages 168-241.
Crossref
Crossref
Mona Yousofshahi, Sara Manteiga, Charmian Wu, Kyongbum Lee & Soha Hassoun. (2015) PROXIMAL: a method for Prediction of Xenobiotic Metabolism. BMC Systems Biology 9:1.
Crossref
Crossref
Terra Arnason & Troy Harkness. (2015) Development, Maintenance, and Reversal of Multiple Drug Resistance: At the Crossroads of TFPI1, ABC Transporters, and HIF1. Cancers 7:4, pages 2063-2082.
Crossref
Crossref
Shinya Hosaka, Norie Murayama, Masahiro Satsukawa, Shotaro Uehara, Makiko Shimizu, Kazuhide Iwasaki, Shunsuke Iwano, Yasuhiro Uno & Hiroshi Yamazaki. (2015) Comprehensive Evaluation for Substrate Selectivity of Cynomolgus Monkey Cytochrome P450 2C9, a New Efavirenz Oxidase. Drug Metabolism and Disposition 43:7, pages 1119-1122.
Crossref
Crossref
Francesco Rua, Giovanna Di Nardo, Sheila J. Sadeghi & Gianfranco Gilardi. (2012)
Toward reduction in animal sacrifice for drugs: Molecular modeling of
Macaca fascicularis
P450 2C20 for virtual screening of
Homo sapiens
P450 2C8 substrates
. Biotechnology and Applied Biochemistry 59:6, pages 479-489.
Crossref
Crossref
Ki Young Lee. (2011) Use of Oral Hypoglycemic Agents in Type 2 Diabetic Patients with Hepatic Dysfunction. Journal of Korean Diabetes 12:4, pages 190.
Crossref
Crossref
G.F. Davies, A.R. Ross, T.G. Arnason, B.H.J. Juurlink & T.A.A. Harkness. (2010) Troglitazone inhibits histone deacetylase activity in breast cancer cells. Cancer Letters 288:2, pages 236-250.
Crossref
Crossref
Jing Zi, Duan Liu, Pingping Ma, He Huang, Juanli Zhu, Dongqing Wei, Jin Yang & Chao Chen. (2010) Effects of CYP2C9*3 and CYP2C9* 13 on Diclofenac Metabolism and Inhibition-based Drug-Drug Interactions. Drug Metabolism and Pharmacokinetics 25:4, pages 343-350.
Crossref
Crossref
Susan Kadlubar & Fred F. Kadlubar. 2010. Enzyme- and Transporter-Based Drug-Drug Interactions. Enzyme- and Transporter-Based Drug-Drug Interactions
3
25
.
Eugen Muschler, Jawahar Lal, Alexander Jetter, Anke Rattay, Ulrich Zanger, Gregor Zadoyan, Uwe Fuhr & Julia Kirchheiner. (2009)
The Role of Human CYP2C8 and CYP2C9 Variants in Pioglitazone Metabolism
In Vitro
. Basic & Clinical Pharmacology & Toxicology 105:6, pages 374-379.
Crossref
Crossref
Julia KirchheinerIngolf MeinekeUwe FuhrCristina Rodríguez-AntonaElena LebedevaJürgen Brockmöller. (2008)
Impact of genetic polymorphisms in
CYP2C8
and rosiglitazone intake on the urinary excretion of dihydroxyeicosatrienoic acids
. Pharmacogenomics 9:3, pages 277-288.
Crossref
Crossref
Dan Rock, Jan Wahlstrom & Larry Wienkers. 2008. Antitargets. Antitargets
195
246
.
Andr?? J Scheen. (2007) Pharmacokinetic Interactions with Thiazolidinediones. Clinical Pharmacokinetics 46:1, pages 1-12.
Crossref
Crossref
Lauri I. Kajosaari, Tiina Jaakkola, Pertti J. Neuvonen & Janne T. Backman. (2006) Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide. European Journal of Clinical Pharmacology 62:3, pages 217-223.
Crossref
Crossref
Grazyna Sobal, E J Menzel & H Sinzinger. (2005) Troglitazone Inhibits Long-Term Glycation and Oxidation of Low-Density Lipoprotein. Journal of Cardiovascular Pharmacology 46:5, pages 672-680.
Crossref
Crossref
Andr?? J Scheen. (2005) Drug Interactions of Clinical Importance with Antihyperglycaemic Agents. Drug Safety 28:7, pages 601-631.
Crossref
Crossref
Chie Emoto, Shigeo Murase, Yasufusa Sawada & Kazuhide Iwasaki. (2005) In Vitro Inhibitory Effect of 1-Aminobenzotriazole on Drug Oxidations in Human Liver Microsomes: a Comparison with SKF-525A. Drug Metabolism and Pharmacokinetics 20:5, pages 351-357.
Crossref
Crossref
Chikako Ishikawa, Hiroshi Ozaki, Toshiaki Nakajima, Toshihiro Ishii, Saburo Kanai, Saeko Anjo, Kohji Shirai & Ituro Inoue. (2004) A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin. Journal of Human Genetics 49:10, pages 582-585.
Crossref
Crossref
Jun Ueyama, Kiyoyuki Kitaichi, Masayuki Nadai, Mitsunori Iwase, Nao Tomyo, Hiroaki Kanazawa, Ryujiro Suzuki, Kenji Takagi, Kenzo Takagi & Takaaki Hasegawa. (2004) Effect of pioglitazone on endotoxin-induced decreases in hepatic drug-metabolizing enzyme activity and expression of CYP3A2 and CYP2C11. European Journal of Pharmacology 498:1-3, pages 257-265.
Crossref
Crossref
Keith G Tolman & Jane Chandramouli. (2003) Hepatotoxicity of the thiazolidinediones. Clinics in Liver Disease 7:2, pages 369-379.
Crossref
Crossref
Jasminder Sahi, Christopher B. Black, Geraldine A. Hamilton, Xianxian Zheng, Summer Jolley, Kelly A. Rose, Darryl Gilbert, Edward L. LeCluyse & Michael W. Sinz. (2003) Comparative Effects of Thiazolidinediones on in Vitro P450 Enzyme Induction and Inhibition. Drug Metabolism and Disposition 31:4, pages 439-446.
Crossref
Crossref
Agneta Hilding, Kerstin Hall, Josefin Skogsberg, Ewa Ehrenborg & Moira S Lewitt. (2003) Troglitazone stimulates IGF-binding protein-1 by a PPARγ-independent mechanism. Biochemical and Biophysical Research Communications 303:2, pages 693-699.
Crossref
Crossref
Padma Kumar Narayanan, Timothy Hart, Fiona Elcock, Cindy Zhang, Laura Hahn, David McFarland, Lester Schwartz, D. Gwyn Morgan & Peter Bugelski. (2003) Troglitazone-induced intracellular oxidative stress in rat hepatoma cells: A flow cytometric assessment. Cytometry 52A:1, pages 28-35.
Crossref
Crossref
Chie Emoto, Shigeo Murase, Yasufusa Sawada, Barry C. Jones & Kazuhide Iwasaki. (2003) In Vitro Inhibitory Effect of 1-Aminobenzotriazole on Drug Oxidations Catalyzed by Human Cytochrome P450 Enzymes: A Comparison with SKF-525A and Ketoconazole. Drug Metabolism and Pharmacokinetics 18:5, pages 287-295.
Crossref
Crossref
Sandra N. Nowak, David J. Edwards, Anthony Clarke, Gail D. Anderson & Linda A. Jaber. (2013) Pioglitazone: Effect on CYP3A4 Activity. The Journal of Clinical Pharmacology 42:12, pages 1299-1302.
Crossref
Crossref
Yuichiro Watanabe, Miki Nakajima & Tsuyoshi Yokoi. (2002) Troglitazone Glucuronidation in Human Liver and Intestine Microsomes: High Catalytic Activity of UGT1A8 and UGT1A10. Drug Metabolism and Disposition 30:12, pages 1462-1469.
Crossref
Crossref
Saileta Prabhu, Andrew Fackett, Scott Lloyd, Holly A McClellan, Chris M Terrell, Paul M Silber & Albert P Li. (2002) Identification of glutathione conjugates of troglitazone in human hepatocytes. Chemico-Biological Interactions 142:1-2, pages 83-97.
Crossref
Crossref
David R. Owens. (2002) Thiazolidinediones. Clinical Drug Investigation 22:8, pages 485-505.
Crossref
Crossref
Loren D. Grossman. (2002) New Solutions for Type 2 Diabetes Mellitus. PharmacoEconomics 20:Supplement 1, pages 1-9.
Crossref
Crossref
Antona J. Wagstaff & Karen L. Goa. (2002) Rosiglitazone. Drugs 62:12, pages 1805-1837.
Crossref
Crossref
Paolo Brunetti. (2016) Pioglitazone — current profile. The British Journal of Diabetes & Vascular Disease 2:1_suppl, pages S18-S23.
Crossref
Crossref
George Steiner. (2001) The use of fibrates and of statins in preventing atherosclerosis in diabetes. Current Opinion in Lipidology 12:6, pages 611-617.
Crossref
Crossref
Thomayant Prueksaritanont, José M. Vega, Jamie Zhao, Kathleen Gagliano, Olga Kuznetsova, Bret Musser, Raju D. Amin, Lida Liu, Brad A. Roadcap, Stacy Dilzer, K. C. Lasseter & J. Douglas Rogers. (2001) Interactions between Simvastatin and Troglitazone or Pioglitazone in Healthy Subjects. The Journal of Clinical Pharmacology 41:5, pages 573-581.
Crossref
Crossref
Peter S. Gillies & Christopher J. Dunn. (2000) Pioglitazone. Drugs 60:2, pages 333-343.
Crossref
Crossref